These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31021388)

  • 21. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
    Choi WM; Choi J; Wong GL; Han S; Lim YS
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87. PubMed ID: 33444532
    [No Abstract]   [Full Text] [Related]  

  • 22. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
    Hsu YC; Ho HJ; Lee TY; Huang YT; Wu MS; Lin JT; Wu CY; El-Serag HB
    J Viral Hepat; 2018 May; 25(5):543-551. PubMed ID: 29193536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Wen Z; Feng Y; Yan X
    J Hepatol; 2021 Jan; 74(1):245-246. PubMed ID: 33008623
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    Papatheodoridis G; Sypsa V; Lampertico P
    J Hepatol; 2021 Jan; 74(1):246-247. PubMed ID: 32988659
    [No Abstract]   [Full Text] [Related]  

  • 25. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
    Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
    J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
    Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
    PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
    Wang JG; Chen R; Wang LC
    Aliment Pharmacol Ther; 2021 May; 53(9):1048-1049. PubMed ID: 33831238
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
    Pol S; Luzivika Nzinga C; Fontaine H; Carrat F;
    Aliment Pharmacol Ther; 2021 Mar; 53(5):659. PubMed ID: 33566398
    [No Abstract]   [Full Text] [Related]  

  • 29. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?
    Yuan BH; Zhu YK; Li RH
    Aliment Pharmacol Ther; 2020 Jan; 51(2):314-315. PubMed ID: 31880015
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
    Lampertico P; Papatheodoridis GV
    Aliment Pharmacol Ther; 2021 Mar; 53(5):657-658. PubMed ID: 33566425
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 32. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
    Yip TC; Wong GL
    Aliment Pharmacol Ther; 2020 Jan; 51(2):315-316. PubMed ID: 31880016
    [No Abstract]   [Full Text] [Related]  

  • 34. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
    Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
    Cho H; Ahn H; Lee DH; Lee JH; Jung YJ; Chang Y; Nam JY; Cho YY; Lee DH; Cho EJ; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Jun; 25(6):707-717. PubMed ID: 29316069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
    Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
    Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
    J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.